Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.63 |
| ▸ | DRD4 | P21917 | 3/20 | 0.63 |
| ▸ | CCR2 | P41597 | 5/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 2/20 | 0.59 |
| ▸ | ACHE | P22303 | 2/20 | 0.59 |
| ▸ | BACE1 | P56817 | 2/20 | 0.59 |
| ▸ | CCR8 | P51685 | 1/20 | 0.56 |
| ▸ | MME | P08473 | 1/20 | 0.54 |
| ▸ | MC4R | P32245 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4962280 | 0.93 | SIGMAR1 (0.69) | DRD4SIGMAR1BCHEACHEBACE1 | |
| SCHEMBL2470379 | 0.81 | MME (0.49) | DRD2DRD4CCR2CCR8MME | |
| SCHEMBL22716940 | 0.81 | DRD2 (0.66) | DRD2DRD4CCR2SIGMAR1BCHE | |
| SCHEMBL2468914 | 0.81 | CCR8 (0.50) | DRD2DRD4BCHEACHEBACE1 | |
| SCHEMBL4962889 | 0.79 | ALDH1A1 (0.63) | MEN1KMT2A | |
| SCHEMBL4962896 | 0.79 | ALDH1A1 (0.63) | MEN1KMT2A | |
| SCHEMBL4971027 | 0.79 | ALDH1A1 (0.63) | MEN1KMT2A | |
| SCHEMBL239528 | 0.79 | DRD4 (0.71) | DRD2DRD4SIGMAR1BCHEACHE | |
| SCHEMBL239527 | 0.79 | DRD4 (0.71) | DRD2DRD4SIGMAR1BCHEACHE | |
| SCHEMBL31616464 | 0.78 | DRD2 (0.73) | DRD2DRD4CCR2SIGMAR1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773780-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | claimed |
| EP-1773780-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012227-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | claimed |
| EP-1773780-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1773780-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006012227-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | DRD2 2127/4885DRD4 3106/4885CCR2 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.